OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

its just a waiting game for now; the SP still keeps rising.

price falling fast, does this mean insiders have wind of the results. Not expecting great results but some announcement with them would boost the sp. Looks like they're going to settle back after all. will be buying again at 35p

Where are you all - I have been expecting some educated comment on this excellent recovery - whats it all about ?? Anyone have a view ?

:-)

no idea

The L&G stake is a good endorsement of this little company, which is not going to remain so little. The raft of Bio products on their roadmap is incredible and It remains my favourite Bio stock and hopefully the one to make me very rich. Any one of their prods could be a blockbuster and transform this company's sp. That and the ever present takeover speculation which is inevitable for such a co with these prospects and the positive newsflow to come i'm sure will propel the sp upward.

robstuff - I wholeheartedly agree. The question though is.....WHEN?????!

ticking up nicely

A new high and not a lot of comment. Yet on the SEO thread, where the price has stabilised between 16 and 20p for some time now there are regularly over 100 posts per day (although admittedly most of them are posters abusing each other). It doesn't seem right somehow...

its hitting new highs every month; this month 50p should be the key resistance level. looking at 70p for christmas. lots of positive news to come.

06/10/05 - 08:17 Oxford Biomedica cites positive TroVax trial data AFX

excellent news:
LONDON (AFX) - Oxford BioMedica PLC, a developer of gene-based medicines,
will on Monday announce new data on Trovax, its lead drug currently being tested
in three separate Phase II trials for use in colorectal cancer.
Nick Woolf, Oxford Bio's senior vice president of corporate strategy, told
AFX News he is confident the news will be positive and believes they are close
to finding a partner to help fund expensive late stage clinical trials and
commercialise the drug once approved.
Oxford BioMedica has been searching for a development partner for Trovax for
a couple of years. It is also being tested for use in renal cancer.
"We're very confident we can get a deal done in '06. It may be this side of
Christmas, but more likely to be next year," he said, speaking at the European
BioPartnering Conference in London yesterday.
He said Oxford BioMedica has been holding talks with "multinational" drug
companies.
Positive data and eventual news of a licensing partner is likely to help the
company's share price, which has already more than doubled this year, from 17.5
pence at the beginning of the year to 42.4 pence today. The company has a market
value of 155 mln stg.
After interim results in August analyst Jon Senior at Evolution Securities
wrote in a note to clients: "Given that the final data from the crucial phase II
trials is due soon and is likely to be followed by the anticipation of a
licensing deal and the start of the phase III trials, we believe the momentum is
likely to stay with BioMedica's share price."
He has an 'add' recommendation on the stock.
BioMedica's Woolf said the company plans to start Phase III trials in the
middle of next year on their own, funded from company resources, even if they
have not found a partner. They can only afford to fund one set of trials --
either in renal or colorectal cancer -- and will announce which will proceed
next year, after agreeing the trial design with US regulators.
"We'll start it on our own if necessary because we're confident a partner
will be found," he said.
Initial data from the colorectal trials, released in March, indicated that
the drug was safe and producing an immune response in patients. Trovax works by
making the immune system recognise a tumour as a foreign body and attack it.
The new data will be presented at the International Colorectal Cancer
Congress, in Florida, this weekend.
According to the US National Cancer Institute colorectal cancer is the third
most common cancer and the second leading cause of cancer related death in the
US.
Woolf also said that ProSavin, a treatment for Parkinson's disease with
should enter the clinic next year, and RetinoStat for age-related macular
degeneration, also in pre-clinical stages, have attracted interest from
potential partners.

huge amount of confidence for their products to state they would go it alone to phase iii trails.

Strange announcing that they are to announce the results on Monday. It appears to me that they maybe trying to raise the price beforehand in order to announce a rights issue at the same time. That would enable them to carry out the trials themselves without delay.

12/10/05 - 14:19 Oxford BioMedica Trovax results due Monday; AFX

Good news bt the sp isn't exactly taking off

Why oh why! - Well into the blue earlier after good news - relaxed had my breakfast and now into red. All we need now is a notice of a Rights Issue.

Oxford Biomedica says TroVax colorectal cancer Phase II trials 'encouraging'
AFX


LONDON (AFX) - Oxford Biomedica PLC reported 'encouraging' results from Phase II trials on its TroVax cancer immunotherapy in metastatic colorectal cancer.

And chief executive Alan Kingsman said the company aims to sign up a development partner for the treatment within the next 12 months. He said the 'promising' trial results 'have been key in our ongoing discussions with prospective partners for TroVax'.

Data from the trials were presented at teh Fourth International Colorectal Cancer Congress in Aventura, Florida.

The presentation included a complete and final analysis of safety and immunology from the two Phase II trials comparing TroVax in combination with standard chemotherapy, against standard chemotherapy alone.

TroVax is designed to prompt the body's immune system to attack tumours.

The company said the results confirm the preliminary conclusions announced in May that the trial had achieved its targets for safety and immunogenicity,and that the secondary target of clinical benefit had exceeded the company's expectations.

newsdesk@afxnews.com

jm/





COPYRIGHT



Copyright AFX News Limited 2005. All rights reserved.

Good news pachandl - so why the sp drop today?

I suppose everyone was expecting even better news - rather than simply "encouraging" news. I should point out that I sold OXB a few weeks ago at about 42p, although I am looking to buy back in at some point. My view was that the sp had got a head of itself and that the "threat" of a rights issue was still definitely on the cards. Needless to say I accept the alternative view that the sp remains in an upward trend and that OXB will sign up a licensing partner within the next year who will fund Ph 111 trials.

Well, whatever the whys and wherefores this was a very poor reaction to some "encouraging" news. I'm disappointed by the market. As always!